26 November 2024 : Clinical Research
Sarcopenia's Role in Neoadjuvant Chemotherapy Outcomes for Locally Advanced Breast Cancer: A Retrospective Analysis
Mustafa Karaca1ACDEF, Mustafa Serkan Alemdar2BDF, Özge Deniz Karaca3ABEF, Yıldız Kılar4BD, Gökhan Köker3BEF, Hasan Sözel5CDE, Mustafa Yıldız2DEF, Gülhan Özçelik Köker1DEF, Mustafa Özgür Arici
2BDEF*
DOI: 10.12659/MSM.945240
Med Sci Monit 2024; 30:e945240
Table 1 Pathologic characteristics of the patients.
| Variables | n | % | |
|---|---|---|---|
| Negative | 68 | 30.1 | |
| Positive | 158 | 69.9 | |
| Negative | 98 | 43.4 | |
| Positive | 128 | 56.6 | |
| Negative | 95 | 42.0 | |
| + | 19 | 8.4 | |
| ++ | 53 | 23.5 | |
| +++ | 59 | 26.1 | |
| Negative | 45 | 19.9 | |
| Positive | 22 | 9.7 | |
| ISH not required | 159 | 70.4 | |
| Negative | 146 | 64.6 | |
| Positive | 80 | 35.4 | |
| Luminal A | 25 | 11.1 | |
| Luminal B | 138 | 61.1 | |
| HER2 | 33 | 14.6 | |
| TNBC | 30 | 13.3 | |
| <14 | 35 | 15.5 | |
| 14 and above | 191 | 84.5 | |
| Absent | 95 | 47.0 | |
| Present | 107 | 53.0 | |
| Absent | 179 | 89.5 | |
| Present | 21 | 10.5 | |
| ER – estrogen receptor; PR – progesterone receptor; HER2 – human epidermal growth factor receptor 2; ISH – in situ hybridization; TNBC – triple-negative breast cancer. | |||